Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Piotr Lewczuk, Sid E. O’Bryant, Marcel M. Verbeek, Bruno Dubois, Pieter Jelle Visser, Kurt A. Jellinger, Sebastiaan Engelborghs, Alfredo Ramirez, Lucilla Parnetti, Clifford R. Jack, Charlotte E. Teunissen, Harald Hampel, Alberto Lleó, Frank Jessen, Lidia Glodzik, Mony J. de Leon, Anne M. Fagan, José Luis Molinuevo, Willemijn J. Jansen, Bengt Winblad & 28 others Leslie M. Shaw, Ulf Andreasson, Markus Otto, Brit Mollenhauer, Jens Wiltfang, Martin R. Turner, Inga Zerr, Ron Handels, Alexander G. Thompson, Gunilla Johansson, Natalia Ermann, John Q. Trojanowski, Ilker Karaca, Holger Wagner, Patrick Oeckl, Linda van Waalwijk van Doorn, Maria Bjerke, H. Bea Kuiperij, Lucia Farotti, Yi Li, Brian A. Gordon, Stéphane Epelbaum, Stephanie J.B. Vos, Catharina J.M. Klijn, William E. Van Nostrand, Carolina Minguillon, Matthias Schmitz, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

Original languageEnglish
Pages (from-to)244-328
Number of pages85
JournalWorld Journal of Biological Psychiatry
Volume19
Issue number4
DOIs
Publication statusPublished - 19 May 2018

Cite this

Lewczuk, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., ... on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut (2018). Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 19(4), 244-328. https://doi.org/10.1080/15622975.2017.1375556
Lewczuk, Piotr ; O’Bryant, Sid E. ; Verbeek, Marcel M. ; Dubois, Bruno ; Visser, Pieter Jelle ; Jellinger, Kurt A. ; Engelborghs, Sebastiaan ; Ramirez, Alfredo ; Parnetti, Lucilla ; Jack, Clifford R. ; Teunissen, Charlotte E. ; Hampel, Harald ; Lleó, Alberto ; Jessen, Frank ; Glodzik, Lidia ; de Leon, Mony J. ; Fagan, Anne M. ; Molinuevo, José Luis ; Jansen, Willemijn J. ; Winblad, Bengt ; Shaw, Leslie M. ; Andreasson, Ulf ; Otto, Markus ; Mollenhauer, Brit ; Wiltfang, Jens ; Turner, Martin R. ; Zerr, Inga ; Handels, Ron ; Thompson, Alexander G. ; Johansson, Gunilla ; Ermann, Natalia ; Trojanowski, John Q. ; Karaca, Ilker ; Wagner, Holger ; Oeckl, Patrick ; van Waalwijk van Doorn, Linda ; Bjerke, Maria ; Kuiperij, H. Bea ; Farotti, Lucia ; Li, Yi ; Gordon, Brian A. ; Epelbaum, Stéphane ; Vos, Stephanie J.B. ; Klijn, Catharina J.M. ; Van Nostrand, William E. ; Minguillon, Carolina ; Schmitz, Matthias ; on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. / Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias : An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. In: World Journal of Biological Psychiatry. 2018 ; Vol. 19, No. 4. pp. 244-328.
@article{ec009ce18b0f45548436f0a353590ada,
title = "Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry",
abstract = "In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.",
keywords = "Alzheimer’s disease, biomarkers, cerebrospinal fluid, consensus, dementia",
author = "Piotr Lewczuk and Peter Riederer and O’Bryant, {Sid E.} and Verbeek, {Marcel M.} and Bruno Dubois and Visser, {Pieter Jelle} and Jellinger, {Kurt A.} and Sebastiaan Engelborghs and Alfredo Ramirez and Lucilla Parnetti and Jack, {Clifford R.} and Teunissen, {Charlotte E.} and Harald Hampel and Alberto Lle{\'o} and Frank Jessen and Lidia Glodzik and {de Leon}, {Mony J.} and Fagan, {Anne M.} and Molinuevo, {Jos{\'e} Luis} and Jansen, {Willemijn J.} and Bengt Winblad and Shaw, {Leslie M.} and Ulf Andreasson and Markus Otto and Brit Mollenhauer and Jens Wiltfang and Turner, {Martin R.} and Inga Zerr and Ron Handels and Thompson, {Alexander G.} and Gunilla Johansson and Natalia Ermann and Trojanowski, {John Q.} and Ilker Karaca and Holger Wagner and Patrick Oeckl and {van Waalwijk van Doorn}, Linda and Maria Bjerke and Dimitrios Kapogiannis and Kuiperij, {H. Bea} and Lucia Farotti and Yi Li and Gordon, {Brian A.} and St{\'e}phane Epelbaum and Vos, {Stephanie J.B.} and Klijn, {Catharina J.M.} and {Van Nostrand}, {William E.} and Carolina Minguillon and Matthias Schmitz and Carla Gallo and {on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut}",
year = "2018",
month = "5",
day = "19",
doi = "10.1080/15622975.2017.1375556",
language = "English",
volume = "19",
pages = "244--328",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

Lewczuk, P, O’Bryant, SE, Verbeek, MM, Dubois, B, Visser, PJ, Jellinger, KA, Engelborghs, S, Ramirez, A, Parnetti, L, Jack, CR, Teunissen, CE, Hampel, H, Lleó, A, Jessen, F, Glodzik, L, de Leon, MJ, Fagan, AM, Molinuevo, JL, Jansen, WJ, Winblad, B, Shaw, LM, Andreasson, U, Otto, M, Mollenhauer, B, Wiltfang, J, Turner, MR, Zerr, I, Handels, R, Thompson, AG, Johansson, G, Ermann, N, Trojanowski, JQ, Karaca, I, Wagner, H, Oeckl, P, van Waalwijk van Doorn, L, Bjerke, M, Kuiperij, HB, Farotti, L, Li, Y, Gordon, BA, Epelbaum, S, Vos, SJB, Klijn, CJM, Van Nostrand, WE, Minguillon, C, Schmitz, M & on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut 2018, 'Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry' World Journal of Biological Psychiatry, vol. 19, no. 4, pp. 244-328. https://doi.org/10.1080/15622975.2017.1375556

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias : An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. / Lewczuk, Piotr; O’Bryant, Sid E.; Verbeek, Marcel M.; Dubois, Bruno; Visser, Pieter Jelle; Jellinger, Kurt A.; Engelborghs, Sebastiaan; Ramirez, Alfredo; Parnetti, Lucilla; Jack, Clifford R.; Teunissen, Charlotte E.; Hampel, Harald; Lleó, Alberto; Jessen, Frank; Glodzik, Lidia; de Leon, Mony J.; Fagan, Anne M.; Molinuevo, José Luis; Jansen, Willemijn J.; Winblad, Bengt; Shaw, Leslie M.; Andreasson, Ulf; Otto, Markus; Mollenhauer, Brit; Wiltfang, Jens; Turner, Martin R.; Zerr, Inga; Handels, Ron; Thompson, Alexander G.; Johansson, Gunilla; Ermann, Natalia; Trojanowski, John Q.; Karaca, Ilker; Wagner, Holger; Oeckl, Patrick; van Waalwijk van Doorn, Linda; Bjerke, Maria; Kuiperij, H. Bea; Farotti, Lucia; Li, Yi; Gordon, Brian A.; Epelbaum, Stéphane; Vos, Stephanie J.B.; Klijn, Catharina J.M.; Van Nostrand, William E.; Minguillon, Carolina; Schmitz, Matthias; on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

In: World Journal of Biological Psychiatry, Vol. 19, No. 4, 19.05.2018, p. 244-328.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias

T2 - An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

AU - Lewczuk, Piotr

AU - Riederer, Peter

AU - O’Bryant, Sid E.

AU - Verbeek, Marcel M.

AU - Dubois, Bruno

AU - Visser, Pieter Jelle

AU - Jellinger, Kurt A.

AU - Engelborghs, Sebastiaan

AU - Ramirez, Alfredo

AU - Parnetti, Lucilla

AU - Jack, Clifford R.

AU - Teunissen, Charlotte E.

AU - Hampel, Harald

AU - Lleó, Alberto

AU - Jessen, Frank

AU - Glodzik, Lidia

AU - de Leon, Mony J.

AU - Fagan, Anne M.

AU - Molinuevo, José Luis

AU - Jansen, Willemijn J.

AU - Winblad, Bengt

AU - Shaw, Leslie M.

AU - Andreasson, Ulf

AU - Otto, Markus

AU - Mollenhauer, Brit

AU - Wiltfang, Jens

AU - Turner, Martin R.

AU - Zerr, Inga

AU - Handels, Ron

AU - Thompson, Alexander G.

AU - Johansson, Gunilla

AU - Ermann, Natalia

AU - Trojanowski, John Q.

AU - Karaca, Ilker

AU - Wagner, Holger

AU - Oeckl, Patrick

AU - van Waalwijk van Doorn, Linda

AU - Bjerke, Maria

AU - Kapogiannis, Dimitrios

AU - Kuiperij, H. Bea

AU - Farotti, Lucia

AU - Li, Yi

AU - Gordon, Brian A.

AU - Epelbaum, Stéphane

AU - Vos, Stephanie J.B.

AU - Klijn, Catharina J.M.

AU - Van Nostrand, William E.

AU - Minguillon, Carolina

AU - Schmitz, Matthias

AU - Gallo, Carla

AU - on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut

PY - 2018/5/19

Y1 - 2018/5/19

N2 - In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

AB - In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

KW - Alzheimer’s disease

KW - biomarkers

KW - cerebrospinal fluid

KW - consensus

KW - dementia

UR - http://www.scopus.com/inward/record.url?scp=85032381406&partnerID=8YFLogxK

U2 - 10.1080/15622975.2017.1375556

DO - 10.1080/15622975.2017.1375556

M3 - Review article

VL - 19

SP - 244

EP - 328

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 4

ER -